At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
|Videos|September 8, 2022
What’s next for Black-tailored prostate cancer risk calculator?
Author(s)Urology Times staff
“[With] some folks, if you don't accurately risk stratify them, you miss your chance to really build that trust as a provider,” says Neil Mistry, MD, MPH.
Advertisement
In this video, Neil Mistry, MD, MPH, and Adam B. Murphy, MD, MBA, MSCI, discuss future research and the take-home message from the abstract, “West-African ancestry can aid prediction of high-grade prostate cancer in Black-tailored risk calculator,” which was presented at the North Central Section of the AUA Annual Meeting in Chicago, Illinois. Mistry is a urology resident and Murphy is an assistant professor of urology and preventive medicine (cancer epidemiology and prevention) at Northwestern University Feinberg School of Medicine in Chicago.
Advertisement
Related to this article
Take a look through some of the notable data presentations at this year's ESMO Congress.
Advertisement
Advertisement
Trending on Urology Times
1
How PSMA-PET shapes staging and recurrence workup in prostate cancer
2
ESMO 2026: Key presentations across genitourinary oncology
3
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
4
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
5